A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.

@article{Deckert2013ANA,
  title={A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.},
  author={Jutta Deckert and Peter U. Park and Sharon Chicklas and Yong Yi and Min Li and Katharine Crane Lai and Michele F. Mayo and Christina N. Carrigan and Hans K. Erickson and Jan Pinkas and Robert J. Lutz and Thomas W. Chittenden and J. G. Lambert},
  journal={Blood},
  year={2013},
  volume={122 20},
  pages={3500-10}
}
CD37 has gathered renewed interest as a therapeutic target in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, CD37-directed antibody-drug conjugates (ADCs) have not been explored. Here, we identified a novel anti-CD37 antibody, K7153A, with potent in vitro activity against B-cell lines through multiple mechanisms including apoptosis induction, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

A phase I study of DCDT2980S, an antibody-drug conjugate (ADC) targeting CD22, in relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) [abstract

  • R Advani, D Lebovic, M Brunvand
  • Blood
  • 2012

A phase I study of the anti-CD79b antibody-drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) [abstract

  • MC Palanca-Wessels, IW Flinn, LH Sehn
  • Blood
  • 2012

Similar Papers

Loading similar papers…